Englander Institute for Precision Medicine 

The Englander Institute for Precision Medicine (EIPM) is a translational research hub where we use precision medicine tools, such as genetics, genomic sequencing, and clinical data to improve patients’ healthcare. Precision medicine can be used as a modern tool to inform physicians of both the treatment and the prevention of genetic-related diseases. This information derives from both the individual genomic sequencing of the patient’s DNA and from the tumor’s cells sequencing. The insights we get can lead to specific genetic alterations that recur from patient to patient and that may be targetable with existing or new drugs. In growing number of cases, we can prognosticate how a patient might respond to a particular drug or drugs combination.

The Institute’s three main resources that enable the EIPM team to most efficiently match new, biologically-targeted therapies to patients who need it are next-generation genomics, biobanking, and computational biology. Our physician-scientists use the most advanced gene-sequencing technologies in our state-of-the-art laboratories to identify the genetic alterations that give rise to and drive each patient’s illness. As an Institute we have already sequenced the genomes of more than 2000 patients and we’re building a comprehensive biobank of tissue samples.

From basic science to drug discoveries and resolving healthcare, the researchers of our institute are working collaboratively across many disciplines with our physician-scientists to realize the full potential of genomic sequencing. This team science approach is critical to advancing treatment and speeding the handoff from discovery to clinical implementation. By linking cutting-edge research and next-generation sequencing in the laboratory to the patient’s bedside, the EIPM hopes to revolutionize the way we treat disease.